HOME >> BIOLOGY >> NEWS
Novel therapeutic bortezomib moves to phase II trial in lung cancer patients

(NEW ORLEANS) -- A three-drug combination including the novel molecularly targeted agent bortezomib, the first drug in its class, proved well-tolerated and showed promising efficacy in patients with advanced non-small cell lung cancer, according to phase I trial results reported Saturday at the annual meeting of the American Society of Clinical Oncologists.

The triple-therapy regimen will now be tested nationally in a phase II trial as first-line therapy for advanced non-small cell lung cancer. Angela Davies, assistant professor of hematology/oncology and principal investigator of the phase I trial, will lead the phase II trial as well.

The regimen consists of bortezomib, gemcitabine and carboplatin. Gemcitabine and carboplatin represent an accepted first-line treatment combination for advanced non-small cell lung cancer.

In the small phase I trial, the three drugs were administered on a similar schedule. Out of 12 patients, four had a partial response and seven had stable disease.

In the larger phase II trial, which will enroll 99 patients, the drugs will be given sequentially, with bortezomib following the chemotherapy drugs. Preclinical research at UC Davis Cancer Center suggests that giving bortezomib last may be more effective than giving it first or at the same time.

Bortezomib is a proteasome inhibitor that blocks the signals cancer cells rely on to degrade cellular proteins. The result is a buildup of proteins that hastens cell death.

Bortezomib has been approved by the Food and Drug Administration for the treatment of multiple myeloma, but had not been tested before in non-small cell lung cancer.

"Bortezomib is an exciting therapeutic, and we're encouraged that we've been able to take this promising three-drug combination immediately from phase I to phase II," Davies said.

Of the estimated 175,000 new cases of lung cancer diagnosed in the United States each year, nearly 80 percent are n
'"/>

Contact: Claudia Morain
530-219-5053
University of California, Davis - Health System
5-Jun-2004


Page: 1 2

Related biology news :

1. Novel IBD therapeutic approaches reported from Washington Univ., Barcelona, LSU at APS meeting
2. Novel approaches to current cellular therapies continue progress toward disease prevention
3. Novel therapies show promise against myeloid leukemia
4. Novel sensors help clear the air
5. Fox Chase Cancer Center study: Novel DNA-repair gene mutation can cause resistance to cancer drugs
6. Novel proteins designed that block inflammation regulator associated with rheumatoid arthritis
7. Novel therapeutic target identified in fight against Rheumatoid Arthritis
8. Novel bacterium detoxifies chlorinated pollutants
9. Novel flu vaccine shows promise in mice
10. Novel gene therapy on the horizon, says Brenner Childrens Hospital pediatrician
11. Novel method identifies hidden genes

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/20/2017)... July 20, 2017 Delta (NYSE: DAL ) customers ... Delta aircraft at Reagan Washington National Airport (DCA). ... Delta launches biometrics to board aircraft ... Delta,s biometric boarding pass ... is now integrated into the boarding process to allow eligible Delta ...
(Date:5/16/2017)... TEANECK, N.J. , May 16, 2017  Veratad ... leading provider of online age and identity verification solutions, ... the K(NO)W Identity Conference 2017, May 15 thru May ... Ronald Regan Building and International Trade Center. ... across the globe and in today,s quickly evolving digital ...
(Date:4/18/2017)... SUNNYVALE, Calif. , April 18, 2017  Socionext Inc., a ... prototype of a media edge server, the M820, which features the ... face recognition software provided by Tera Probe, Inc., will be showcased ... and at the NAB show at the Las Vegas ... ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... , ... October 11, 2017 , ... ... the implantation and pregnancy rates in frozen and fresh in vitro fertilization ... progesterone and maternal age to IVF success. , After comparing the results from ...
(Date:10/10/2017)... , ... October 10, 2017 , ... ... Center’s FirstHand program has won a US2020 STEM Mentoring Award. Representatives of the ... for Excellence in Volunteer Experience from US2020. , US2020’s mission is to change ...
(Date:10/10/2017)... CALIFORNIA (PRWEB) , ... October 10, 2017 , ... ... technological innovation and business process optimization firm for the life sciences and healthcare ... BoxWorks conference in San Francisco. , The presentation, “Automating GxP Validation for ...
(Date:10/9/2017)... ... ... At its national board meeting in North Carolina, ARCS® Foundation ... Physics and Astronomy, has been selected for membership in ARCS Alumni Hall of ... Breakthrough Prize in Fundamental physics for the discovery of the accelerating expansion of the ...
Breaking Biology Technology:
Cached News: